---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Heterogeneity of treatment effect"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Heterogeneity of treatment effect. Topics: Lorundrostat subgroups in Launch-HTN: age, sex, race, body mass index, and number of background drugs; Lorundrostat subgroups in Launch-HTN: ICER assessment; Lorundrostat by chronic kidney disease status in Launch-HTN; Lorundrostat by chronic kidney disease stage in Launch-HTN: placebo-adjusted change at week 12; 8 further topics. 13 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description/heterogeneity-of-treatment-effect"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Heterogeneity of treatment effect

<a id="heading-2.2.2.3"></a>

## 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

### Summary

- Lorundrostat: In Launch-HTN, the blood pressure effect of lorundrostat 50 mg was consistent across age, sex, race, body mass index, and number of background antihypertensive drugs. The placebo-adjusted change in office systolic blood pressure at week 6 was −8.8 mm Hg in participants taking 2 drugs and −9.0 mm Hg in those taking 3 or more. In a Launch-HTN analysis by chronic kidney disease (CKD) status, the placebo-adjusted reduction at week 12 was −12.2 mm Hg without CKD and −9.6 mm Hg with CKD stages 1 to 3; confirmed serum potassium above 6.0 mmol/L occurred in 3 (2.4%) participants with CKD and none without CKD. In the phase 2 Target-HTN trial, prespecified exploratory subgroups showed larger reductions in participants with a body mass index above 30 than in those with a body mass index of 25 to 30, and attenuated reductions in participants not taking a diuretic; participants with nonsuppressed plasma renin (exploratory cohort 2) had a reduction similar to those with suppressed renin at 100 mg. In Explore-OSA, participants with obesity and moderate-to-severe obstructive sleep apnea had a placebo-adjusted office systolic reduction of 10.1 mm Hg in the parallel-arm analysis.
- Class evidence: ICER reported consistent baxdrostat effects across all prespecified subgroups in BaxHTN and Bax24, similar aldosterone synthase inhibitor effects in participants taking two versus three or more background drugs, and no differential blood pressure lowering by mineralocorticoid antagonists between resistant and non-resistant hypertension. In a randomized crossover trial in resistant hypertension, spironolactone lowered blood pressure most across the distribution of baseline plasma renin, with a margin of superiority many-fold greater at the lower end, and plasma renin and the aldosterone-to-renin ratio predicted the home systolic response.
- Limits of the evidence: The pivotal aldosterone synthase inhibitor trials excluded people with advanced CKD. ICER reports hearing that differences in treatment effect by race or ethnicity are small and not likely to be clinically significant. Target-HTN subgroup analyses were exploratory.

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/); [Vogt et al. (2026)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.2026fy6zb248~blood-pressure-and-albuminuria-reduction-with-lorundrostat); [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/); [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08); [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf); [Williams et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4655321/); [Williams et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5966620/)

<a id="topic-2.2.2.3-2"></a>

### Lorundrostat subgroups in Launch-HTN: age, sex, race, body mass index, and number of background drugs

> “The efficacy of lorundrostat for lowering BP was consistent across age, sex, race, BMI, and number of prescribed antihypertensive medications participants were taking (Figure 3).”
> “Compared with placebo, the least-squares mean change in office systolic BP at week 6 was −8.8 mm Hg (97.5% CI, −14.8 to −2.9 mm Hg; P < .001) for participants in the pooled 50 mg of lorundrostat group taking 2 prescribed antihypertensive medications.”
> “Compared with placebo, the least-squares mean change in office systolic BP at week 6 was −9.0 mm Hg (97.5% CI, −14.0 to −4.1 mm Hg; P < .001) for participants in the pooled 50 mg of lorundrostat group taking 3 or more antihypertensive medications.”
> “A comparable reduction in office systolic BP was observed across the continuum of BMI represented in the trial; 91.6% of participants had a BMI of 25 or greater.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-2.2.2.3-3"></a>

### Lorundrostat subgroups in Launch-HTN: ICER assessment

> “In the Launch-HTN study, treatment effects between lorundrostat and placebo at week six were consistent across the subgroups of age, sex, race, baseline SBP, BMI, waist-to-hip ratio, and eGFR”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.2.3-4"></a>

### Lorundrostat by chronic kidney disease status in Launch-HTN

> “CKD was defined as eGFR <60mL/min/1.73m2 or UACR ≥30mg/g.”
> “Placebo-adjusted reduction in AOSBP was -12.2 mmHg and -9.6 mmHg in participants without and with CKD, respectively (Table).”
> “Among participants receiving LOR 50mg, confirmed serum potassium >6.0 mmol/L occurred in 3 (2.4%) CKD participants and in none of the non-CKD participants.”

Source: [Vogt et al. (2026)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.2026fy6zb248~blood-pressure-and-albuminuria-reduction-with-lorundrostat)

<a id="topic-2.2.2.3-5"></a>

### Lorundrostat by chronic kidney disease stage in Launch-HTN: placebo-adjusted change at week 12

| CKD stage | Lorundrostat 50 mg participants | Placebo-adjusted AOSBP change, mm Hg (95% CI) | Week 12 % with AOSBP <130 mmHg, lorundrostat 50 mg |
| --- | --- | --- | --- |
| No CKD | “N=406” | “-12.2 (-17.1, -7.3)” | “48.0” |
| Stage 1 | “N=58” | “-10.6 (-18.6, -2.6)” | “50.6” |
| Stage 2 | “N=31” | “-7.6 (-16.5, 1.4)” | “28.4” |
| Stage 3 | “N=38” | “-10.1 (-21.1, 1.0)” | “47.0” |

Source: [Vogt et al. (2026)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.2026fy6zb248~blood-pressure-and-albuminuria-reduction-with-lorundrostat)

<a id="topic-2.2.2.3-6"></a>

### Lorundrostat by obesity and diuretic use in Target-HTN

> “Analysis of the primary end point was repeated in each prespecified subgroup, and these analyses were considered exploratory.”
> “Individuals with a BMI greater than 30 randomized to 50 mg once daily of lorundrostat demonstrated a −16.7 mm Hg (90% CI, −25.5 to −7.9 mm Hg) change in systolic AOBP compared with placebo.”
> “Among individuals with a BMI of 25 to 30, the BP changes were 2.2 mm Hg (90% CI, −7.4 to 11.8 mm Hg) and −4.5 (90% CI, −14.5 to 5.5 mm Hg) for the 50-mg and 100-mg once-daily doses, respectively.”
> “Blood pressure decreases were attenuated among participants not taking a diuretic”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-2.2.2.3-7"></a>

### Lorundrostat by plasma renin status in Target-HTN

> “Participants with PRA of greater than 1.0 ng/mL/h (cohort 2) randomized to 100 mg once daily of lorundrostat demonstrated a similar change in mean systolic AOBP of −11.4 (SD, 2.5) mm Hg compared with those randomized to 100 mg once daily with suppressed plasma renin in cohort 1.”
> “Because cohort 2 was an exploratory end point, no formal statistical testing was performed comparing lorundrostat with placebo.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-2.2.2.3-8"></a>

### Lorundrostat in obstructive sleep apnea with obesity

> “In a preplanned parallel arm analysis of the first treatment period providing a point estimate of efficacy, the placebo-adjusted reduction in SBP with lorundrostat was 10.1 mmHg (P=0.0089).”
> “A clinically meaningful reduction in office SBP in adults with moderate-to-severe OSA and hypertension was seen, with similar magnitude compared with prior pivotal lorundrostat treatment trials in patients with uHTN.”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="topic-2.2.2.3-9"></a>

### Number of background antihypertensive drugs: class evidence used by ICER

> “First, subgroup analyses from baxdrostat and lorundrostat studies showed similar treatment effects among patients taking two versus three or more antihypertensive medications at baseline.”
> “Second, a meta-analysis of mineralocorticoid antagonists found no differential blood pressure lowering between resistant and non-resistant hypertension”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.2.3-10"></a>

### Baxdrostat subgroups

> “In the BaxHTN and Bax24 studies, treatment effects between baxdrostat and placebo on SBP at week 12 were consistent across all prespecified subgroups (age, sex, race, ethnicity, geographic region, baseline SBP, eGFR, and BMI).”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.2.3-11"></a>

### Spironolactone response by plasma renin

> “Spironolactone was the most effective blood pressure-lowering treatment, throughout the distribution of baseline plasma renin; but its margin of superiority and likelihood of being the best drug for the individual patient were many-fold greater in the lower than higher ends of the distribution.”

Source: [Williams et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4655321/)

> “Home systolic blood pressure reduction by spironolactone was predicted by ARR (r2=0·13, p<0·0001) and plasma renin (r2=0·11, p=0·00024).”

Source: [Williams et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5966620/)

<a id="topic-2.2.2.3-12"></a>

### Race and ethnicity: clinician input to ICER

> “we heard that although there may be differences in treatment effects by race or ethnicity, those differences are small and not likely to be clinically significant.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.2.3-13"></a>

### Advanced chronic kidney disease excluded from pivotal trials

> “The pivotal trials for baxdrostat and lorundrostat excluded subgroups such as those with advanced chronic kidney disease.”
> “Ongoing studies may address whether ASIs are effective and safe in such subgroups.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
